<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931576</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0316</org_study_id>
    <nct_id>NCT04931576</nct_id>
  </id_info>
  <brief_title>No Drainage During Transoral Endoscopic Thyroidectomy Vestibular Approach(TOETVA)</brief_title>
  <official_title>The Feasibility of no Drainage During Transoral Endoscopic Thyroidectomy Via the Vestibular Approach in Treatment of Papillary Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the viability and safety of no drainage tube placement during transoral&#xD;
      endoscopic thyroidectomy vestibular approach in treatment of patients with papillary thyroid&#xD;
      carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transoral endoscopic thyroidectomy vestibular approach (TOETVA) is widely used due to its&#xD;
      excellent cosmetic effect without scars on the body surface. In prevention of postoperative&#xD;
      hemorrhage, a postoperative drainage tube is routinely placed in the surgical area. However,&#xD;
      current opinion suggest that under the circumstance of strict and effective intraoperative&#xD;
      hemostasis, routine application of drainage tube is unnecessary in conventional open&#xD;
      thyroidectomy(COT). The research about drainage placement decision during endoscopic&#xD;
      thyroidectomy is scarce currently. This study evaluates the viability and safety of no&#xD;
      drainage tube placement during TOETVA on papillary thyroid carcinoma.&#xD;
&#xD;
      Patients allocated to the intervention group will implace no drainage tube during TOETVA and&#xD;
      those allocated in control group will implace one drainage tube routinely.&#xD;
&#xD;
      The incidence of postoperative complications will be evaluated. The time of postoperative&#xD;
      hospital-stay and operation time will be evaluated as well. At the same time, blood test&#xD;
      results like WBC and CRP will be evaluated 1 day after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence rate of hemorrhage on week 1 after surgery</measure>
    <time_frame>1 week</time_frame>
    <description>To evaluate the incidence rate of postoperative hemorrhage (hemorrhage of surgical sites which requires reoperation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence rate of infections on week 2 after surgery</measure>
    <time_frame>2 week</time_frame>
    <description>To evaluate the incidence rate of infections of surgical sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence rate of postoperative hematoma or seroma on week 2 after surgery</measure>
    <time_frame>2 week</time_frame>
    <description>To evaluate the incidence rate of postoperative hematoma or seroma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain score on day 1 after surgery</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate the pain score via numerical rating scale on day 1 after surgery. An 11-point numeric scale (NRS 11) with 0 representing no pain and 10 representing worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature on day 1 after surgery</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate the body temperature on day 1 after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WBC on day 1 after surgery</measure>
    <time_frame>1 day</time_frame>
    <description>To evaluate the white blood count on day 1 after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP on day 1 after surgery</measure>
    <time_frame>1 week</time_frame>
    <description>To evaluate the C-reaction protein on day 1 after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of post-operative hospital stay</measure>
    <time_frame>1 week</time_frame>
    <description>To evaluate the length of post-operative hospital stay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Drainage</condition>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Routine application of drainage tube</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After TOETVA, patients will receive one drainage tube through anterior cervical area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omission of drainage tube</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After TOETVA, patients will receive complete omission of drianage tube and directly close the incision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>no drainage tube applied</intervention_name>
    <description>No drainage tube implacement after TOETVA</description>
    <arm_group_label>Omission of drainage tube</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing thyroid surgery for the first time&#xD;
&#xD;
          2. The surgical method is TOETVA&#xD;
&#xD;
          3. There is no lateral cervical lymph node metastasis assessed before surgery&#xD;
&#xD;
          4. Fine-needle aspiration revealed palpilary thyroid carcinoma&#xD;
&#xD;
          5. It meets the surgical indications and has no obvious surgical contraindications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. previous history of thyroid surgery;&#xD;
&#xD;
          2. conventional open thyroidectomy, endoscopic thyroidectomy areola approach or axillary&#xD;
             approach;&#xD;
&#xD;
          3. patients undergoing cervical lateral lymph node dissection;&#xD;
&#xD;
          4. past or current history of hyperthyroidism;&#xD;
&#xD;
          5. history of combined hypertension, diabetes, coagulation dysfunction, or other&#xD;
             important organ dysfunction diseases.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Zhiyu, Ph.D</last_name>
    <phone>+86-13858169479</phone>
    <email>drlizy@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang Jingying, Ph.D</last_name>
    <phone>+86-15068803975</phone>
    <email>jyzhang_hz@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Schietroma M, Pessia B, Bianchi Z, De Vita F, Carlei F, Guadagni S, Amicucci G, Clementi M. Thyroid Surgery: To Drain or Not to Drain, That Is the Problem - A Randomized Clinical Trial. ORL J Otorhinolaryngol Relat Spec. 2017;79(4):202-211. doi: 10.1159/000464137. Epub 2017 Jul 15.</citation>
    <PMID>28715809</PMID>
  </reference>
  <reference>
    <citation>Soh TCF, Ong QJ, Yip HM. Complications of Neck Drains in Thyroidectomies: A Systematic Review and Meta-Analysis. Laryngoscope. 2021 Mar;131(3):690-700. doi: 10.1002/lary.29077. Epub 2020 Oct 6.</citation>
    <PMID>33022081</PMID>
  </reference>
  <reference>
    <citation>Fernandez Ranvier G, Meknat A, Guevara DE, Llorente PM, Vidal Fortuny J, Sneider M, Chen YH, Inabnet W 3rd. International Multi-institutional Experience with the Transoral Endoscopic Thyroidectomy Vestibular Approach. J Laparoendosc Adv Surg Tech A. 2020 Mar;30(3):278-283. doi: 10.1089/lap.2019.0645. Epub 2020 Jan 17.</citation>
    <PMID>31951503</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drainage</keyword>
  <keyword>TOETVA</keyword>
  <keyword>Palpilary Thyroid Carcinoma</keyword>
  <keyword>complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

